期刊文献+

Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives 被引量:1

原文传递
导出
摘要 Diabetes,characterized by hyperglycemia,is a major cause of death and disability worldwide.Peptides,such as insulin and glucagon-like peptide-1(GLP-1)analogs,have shown promise as treatments for diabetes due to their ability to mimic or enhance insulin's actions in the body.Compared to subcutaneous injection,oral administration of anti-diabetic peptides is a preferred approach.However,biological barriers significantly reduce the efficacy of oral peptide therapeutics.Recent advancements in drug delivery systems and formulation techniques have greatly improved the oral delivery of peptide therapeutics and their efficacy in treating diabetes.This review will highlight(1)the benefits of oral anti-diabetic peptide therapeutics;(2)the biological barriers for oral peptide delivery,including pH and enzyme degradation,intestinal mucosa barrier,and biodistribution barrier;(3)the delivery platforms to overcome these biological barriers.Additionally,the review will discuss the prospects in this field.The information provided in this review will serve as a valuable guide for future developments in oral anti-diabetic peptide therapeutics.
出处 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2024年第5期2006-2025,共20页 药学学报(英文版)
基金 This study was supported by the National Science Fund of Distinguished Young Scholars(No.82025032,China) the National Natural Science Foundation of China(No.82073773,China) the Key Research Program of Chinese Academy of Sciences(ZDBS-ZRKJZ-TLC005,China) Young Elite Scientists Sponsorship Program by CAST(No.2022QNRC001,China).
  • 相关文献

参考文献9

二级参考文献29

共引文献67

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部